ArticleJournal of thoracic disease2025
Diagnostic accuracy of interleukin 32γ for tuberculous pleural effusion.
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pleural fluid C-C motif chemokine ligand 2 as a diagnostic biomarker for malignant pleural effusion.Journal of thoracic disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Accurate diagnosis of tuberculous pleural effusion (TPE) with biomarkers remains difficult. Interleukin 32gamma (IL-32γ) is a recently discovered proinflammatory cytokines which plays a vital role in the immune response to TPE. This study aimed to assess the diagnostic accuracy of IL-32γ for TPE, especially in different ages of patients. Methods: Patients with a confirmed diagnosis of pleural effusion were systematically recruited from Beijing Chao-Yang Hospital between June 2019 and May 2022. The concentration of IL-32γ and interferon-gamma (IFN-γ) were evaluated in the pleural effusions with different etiology from 188 patients using enzyme-linked immunosorbent assay method. Adenosine deaminase (ADA) was determined by peroxidase method. Results: At a threshold value of 181.56 ng/L, IL-32γ demonstrated an area under the curve (AUC) of 0.812 [95% confidence interval (CI): 0.748-0.865], with sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), positive predictive value (PPV), and negative predictive value (NPV) of 70.2%, 86.0%, 5.0, 0.4, 92.0%, and 55.7%, respectively. In elderly patients (aged >65 years), IL-32γ demonstrated an AUC of 0.984 (95% CI: 0.891-1.000). Notably, the diagnostic accuracy of IL-32γ was significantly higher than that of ADA (P=0.03) and IFN-γ (P=0.02). Similarly, the AUCs for IL-32γ combined with ADA (0.981, 95% CI: 0.886-1.000) and IL-32γ combined with IFN-γ (1.000, 95% CI: 0.920-1.000) were significantly higher than those of ADA (P=0.04) or IFN-γ (P=0.01) alone in elderly patients. Conclusions: IL-32γ can be used as a valuable biomarker for identifying patients with TPE, especially in elderly patients aged >65 years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.